aibio
Listings ·
Mustang Bio gets a second 180-day Nasdaq grace period to fix its bid price
Nasdaq gave Mustang Bio until April 12, 2027 to lift its bid price to $1.00. The company has said it intends to do a reverse stock split if necessary.
MBIO Mustang Bio, Inc.
Mustang Bio (MBIO) news MBIO reverse split, offering and Nasdaq notice news
Latest Mustang Bio news
- Listings
Mustang Bio receives Nasdaq bid price deficiency notice
Mustang Bio's common stock closed below $1.00 for 30 consecutive business days, and the company has until October 12, 2026 to regain compliance with the Nasdaq minimum bid price rule.
- Mergers
Mustang Bio sells Worcester equipment to AbbVie for $1.0 million and exits facility lease
Mustang Bio received the $1.0 million purchase price from escrow on February 25, 2025. It expects about $2.0 million in cash savings on the lease over the next 24 months and has moved its headquarters to Waltham.
- Mergers
Mustang Bio sells fixed assets to AbbVie for $1.0 million and exits Worcester facility
The company expects about $2.0 million in lease savings over 24 months. It has moved its headquarters to Waltham, Massachusetts.
- Financings
Mustang Bio prices $8 million offering at $3.01 with two series of warrants
The warrants can be exercised only after stockholders approve. The offering follows a 1-for-50 reverse stock split on January 15, 2025.
What Mustang Bio does
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that aims to license or acquire technologies for difficult-to-treat cancers, fund their research and development, and then out-license them or bring them to market. Its pipeline focuses on novel therapies for solid tumors and is developed under exclusive licenses from City of Hope National Medical Center and Nationwide Children's Hospital. MB-101 is an IL13Rα2-targeted CAR T therapy for solid tumors, and MB-108 is an HSV-1 oncolytic virus. The two are combined in MB-109 for IL13Rα2-positive recurrent glioblastoma and high-grade astrocytoma, for which the FDA issued a safe-to-proceed letter for an IND in October 2023. Phase 1 trials sponsored by City of Hope for MB-101 and by the University of Alabama at Birmingham for MB-108 have completed their treatment phases. The company has not received approval for the sale of any product candidate and reported an accumulated deficit of $398.6 million as of December 31, 2025. Mustang is a majority-controlled subsidiary of Fortress Biotech, Inc. After its Worcester cell processing facility lease was terminated, it is exploring an investigator-sponsored MB-109 study at City of Hope in the second quarter of 2026.
| Product or program | What it is | Stage |
|---|---|---|
| MB-101 | IL13Rα2-targeted CAR T cell therapy for solid tumors and glioblastoma | Phase 1 treatment phase completed; patients assessed for long-term safety |
| MB-108 | HSV-1 oncolytic virus for malignant brain tumors | Phase 1 treatment phase completed |
| MB-109 | Combination of MB-101 and MB-108 for recurrent glioblastoma | IND safe-to-proceed letter from the FDA in October 2023 |
Mustang Bio annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$1.9 million | -$15.8 million |
| Cash from operations | -$5.3 million | -$11.4 million |
| Cash and equivalents | $17.3 million | $6.8 million |
Questions about Mustang Bio
Did Mustang Bio do a reverse stock split?
Our latest story on this, dated Oct 15, 2026: "Mustang Bio gets a second 180-day Nasdaq grace period to fix its bid price". The story links the filing or release it is based on. Read the story.
Has Mustang Bio raised money recently?
Our latest story on this, dated Feb 7, 2025: "Mustang Bio prices $8 million offering at $3.01 with two series of warrants". The story links the filing or release it is based on. Read the story.
Has Mustang Bio received a Nasdaq deficiency notice?
Our latest story on this, dated Apr 15, 2026: "Mustang Bio receives Nasdaq bid price deficiency notice". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Mustang Bio?
Mustang Bio, Inc. trades under the ticker MBIO on NASDAQ.
Where is Mustang Bio listed?
Mustang Bio, Inc. is listed on NASDAQ.
What is the SEC CIK of Mustang Bio?
The SEC Central Index Key (CIK) for Mustang Bio, Inc. is 1680048. Its filings are on SEC EDGAR.
How many shares does Mustang Bio have outstanding?
24,976,289 shares as of 2017-03-30, per the cover page of its 10-K filed 2017-03-31.
Which country or territory is Mustang Bio listed under?
Our directory records Mustang Bio, Inc. under United States.
What does Mustang Bio do?
Our directory classifies Mustang Bio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Mustang Bio?
The ISIN recorded for Mustang Bio, Inc. is US62818Q3020.
Does aibio.space cover Mustang Bio?
aibio.space lists Mustang Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Mustang Bio incorporated?
SEC records list its state or country of incorporation as DE.
What does Mustang Bio develop?
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that aims to license or acquire technologies for difficult-to-treat cancers, fund their research and development, and then out-license them or bring them to market. Its pipeline focuses on novel therapies for solid tumors and is developed under exclusive licenses from City of Hope National Medical Center and Nationwide Children's Hospital.
What is MB-101 from Mustang Bio?
MB-101: IL13Rα2-targeted CAR T cell therapy for solid tumors and glioblastoma Stage: Phase 1 treatment phase completed; patients assessed for long-term safety.
What is MB-108 from Mustang Bio?
MB-108: HSV-1 oncolytic virus for malignant brain tumors Stage: Phase 1 treatment phase completed.
Investor discussion: Mustang Bio
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
- Mergers
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,8.01,9.01). Source
- Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). Source
- Financings
Reported a financing. SEC Form 424B4. Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
- Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02). Source
Stock chart
SEC filings and registration
- SEC name
- Mustang Bio, Inc.
- CIK
- 1680048
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- MBIO (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 95 SAWYER RD, WALTHAM, MA, 02453
- Phone
- 7816524500
- Shares outstanding
- 24,976,289 as of 2017-03-30 (10-K filed 2017-03-31)
Recent filings
Listing details
- Company
- Mustang Bio, Inc.
- Ticker
- MBIO
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US62818Q3020
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction